Skip to main content

SYRS

Stock
Health Care
Biotechnology

Performance overview

SYRS Price
Price Chart

Forward-looking statistics

Beta
1.56
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees100
Market cap$137.7M

Fundamentals

Enterprise value$2.5M
Revenue$386.0K
Revenue per employee
Profit margin0.00%
Debt to equity-5.41

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.07
Dividend per share
Revenue per share$0.01
Avg trading volume (30 day)$2K
Avg trading volume (10 day)$2K
Put-call ratio

Macro factor sensitivity

Growth+0.7
Credit+5.3
Liquidity+2.2
Inflation-4.3
Commodities-1.1
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-0.01
Price to sales1.74
P/E Ratio-0.01
Enterprise Value to Revenue6.60
Price to book-0.09

Upcoming events

Next earnings dayMay 14, 2024
Next dividend day
Ex. dividend day

News

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

Zacks Investment Research (November 14, 2024)
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.

Benzinga (November 13, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free